MX2023001948A - Inmunogenicidad mejorada de conjugados de polisacarido-proteina de streptococcus pneumoniae. - Google Patents
Inmunogenicidad mejorada de conjugados de polisacarido-proteina de streptococcus pneumoniae.Info
- Publication number
- MX2023001948A MX2023001948A MX2023001948A MX2023001948A MX2023001948A MX 2023001948 A MX2023001948 A MX 2023001948A MX 2023001948 A MX2023001948 A MX 2023001948A MX 2023001948 A MX2023001948 A MX 2023001948A MX 2023001948 A MX2023001948 A MX 2023001948A
- Authority
- MX
- Mexico
- Prior art keywords
- protein conjugates
- polysaccharide
- streptococcus pneumoniae
- protein
- pneumoniae polysaccharide
- Prior art date
Links
- 241000193998 Streptococcus pneumoniae Species 0.000 title abstract 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 title abstract 2
- 230000002708 enhancing effect Effects 0.000 title 1
- 230000005847 immunogenicity Effects 0.000 title 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract 6
- 150000004676 glycans Chemical class 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229920001282 polysaccharide Polymers 0.000 abstract 2
- 239000005017 polysaccharide Substances 0.000 abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 108010060123 Conjugate Vaccines Proteins 0.000 abstract 1
- 239000000010 aprotic solvent Substances 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/116—Polyvalent bacterial antigens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente invención proporciona composiciones inmunogénicas que tienen uno o más conjugados de polisacárido-proteína en los cuales uno o más polisacáridos de cápsulas bacterianas de Streptococcus pneumoniae se conjugan con una proteína vehículo en un solvente aprótico tal como dimetilsulfóxido (DMSO). La presente invención también proporciona métodos para proporcionar una respuesta inmunitaria mejorada a una vacuna de conjugado de polisacárido-proteína neumococo que comprende administrar a un sujeto humano una composición inmunogénica que comprende conjugados de polisacárido-proteína preparados en condiciones de DMSO.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762463216P | 2017-02-24 | 2017-02-24 | |
US201762555444P | 2017-09-07 | 2017-09-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023001948A true MX2023001948A (es) | 2023-03-14 |
Family
ID=63254065
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019009867A MX2019009867A (es) | 2017-02-24 | 2018-02-20 | Inmunogenicidad mejorada de conjugados de polisacarido-proteina de streptococcus pneumoniae. |
MX2023001947A MX2023001947A (es) | 2017-02-24 | 2019-08-19 | Inmunogenicidad mejorada de conjugados de polisacarido-proteina de streptococcus pneumoniae. |
MX2023001948A MX2023001948A (es) | 2017-02-24 | 2019-08-19 | Inmunogenicidad mejorada de conjugados de polisacarido-proteina de streptococcus pneumoniae. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019009867A MX2019009867A (es) | 2017-02-24 | 2018-02-20 | Inmunogenicidad mejorada de conjugados de polisacarido-proteina de streptococcus pneumoniae. |
MX2023001947A MX2023001947A (es) | 2017-02-24 | 2019-08-19 | Inmunogenicidad mejorada de conjugados de polisacarido-proteina de streptococcus pneumoniae. |
Country Status (10)
Country | Link |
---|---|
US (4) | US11090374B2 (es) |
EP (1) | EP3589314A4 (es) |
JP (3) | JP2020514326A (es) |
KR (2) | KR20190121330A (es) |
CN (1) | CN110337307A (es) |
AU (1) | AU2018225099B2 (es) |
BR (1) | BR112019017560A2 (es) |
CA (1) | CA3050120A1 (es) |
MX (3) | MX2019009867A (es) |
WO (1) | WO2018156491A1 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL308456A (en) * | 2005-04-08 | 2024-01-01 | Wyeth Llc | A multivalent pneumomuroral protein-polysaccharide conjugate preparation |
EP3957321A3 (en) | 2014-01-21 | 2022-07-13 | Pfizer Inc. | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
PE20240927A1 (es) * | 2015-07-21 | 2024-04-30 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos |
KR20190103256A (ko) | 2016-12-30 | 2019-09-04 | 수트로박스, 인코포레이티드 | 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체 |
US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
KR102650073B1 (ko) | 2017-01-31 | 2024-03-20 | 머크 샤프 앤드 돔 엘엘씨 | 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법 |
US11197921B2 (en) | 2017-01-31 | 2021-12-14 | Merck Sharp & Dohme Corp. | Methods for making polysaccharide-protein conjugates |
US11400162B2 (en) | 2017-02-24 | 2022-08-02 | Merck Sharp & Dohme Llc | Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein |
US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
AU2018328036B2 (en) * | 2017-09-07 | 2024-03-07 | Merck Sharp & Dohme Llc | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
WO2019050816A1 (en) | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER |
US11524076B2 (en) | 2017-09-07 | 2022-12-13 | Merck Sharp & Dohme Llc | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
CA3074703A1 (en) | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
CN117982633A (zh) | 2017-12-06 | 2024-05-07 | 默沙东有限责任公司 | 包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法 |
WO2019212844A1 (en) | 2018-04-30 | 2019-11-07 | Merck Sharp & Dohme Corp. | Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide |
EP3787673A4 (en) | 2018-04-30 | 2022-04-27 | Merck Sharp & Dohme Corp. | METHODS FOR PRODUCING CAPSULAR CARRIER PROTEIN-POLYSACCHARIDE CONJUGATES OF STREPTOCOCCUS PNEUMONIAE |
BR112021005425A2 (pt) * | 2018-09-23 | 2021-06-15 | Biological E Limited | polissacarídeos capsulares purificados de streptococcus pneumoniae |
SG11202106541WA (en) | 2018-12-19 | 2021-07-29 | Merck Sharp & Dohme | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
CA3136278A1 (en) * | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
BR112021024393A8 (pt) * | 2019-06-05 | 2023-01-31 | Merck Sharp & Dohme | Um conjugado de polissacarídeo-proteína pneumocócico de sorotipo 35b imunogênico e processo de conjugação para fabricar o mesmo |
CN110804097B (zh) * | 2019-10-30 | 2021-02-26 | 云南沃森生物技术股份有限公司 | 一种同时制备两种单克隆抗体的方法 |
EP4101192A4 (en) * | 2020-02-03 | 2024-02-28 | Anagog Ltd. | DELIVERY OF DISTRIBUTED CONTENT |
EP4143564B1 (en) * | 2020-04-28 | 2024-06-05 | Janssen Pharmaceuticals, Inc. | Method for identification and quantification of polysaccharides in complex glycoconjugate compositions |
JP2023549736A (ja) | 2020-11-10 | 2023-11-29 | ファイザー・インク | コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用 |
WO2022249107A2 (en) * | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
CN114965784B (zh) * | 2022-06-01 | 2023-10-27 | 艾美探索者生命科学研发有限公司 | 多糖活化度的测定方法 |
WO2024059161A1 (en) * | 2022-09-16 | 2024-03-21 | Merck Sharp & Dohme Llc | Method for quantification of polysaccharide content in conjugate vaccines |
US20240181028A1 (en) | 2022-11-22 | 2024-06-06 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0220198D0 (en) * | 2002-08-30 | 2002-10-09 | Chiron Spa | Modified saccharides,conjugates thereof and their manufacture |
US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US7709001B2 (en) * | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
CN101155833B (zh) | 2005-04-08 | 2011-04-20 | 惠氏公司 | 通过pH操作将污染物与肺炎链球菌多糖分离 |
IL308456A (en) | 2005-04-08 | 2024-01-01 | Wyeth Llc | A multivalent pneumomuroral protein-polysaccharide conjugate preparation |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
US8808707B1 (en) | 2006-05-08 | 2014-08-19 | Wyeth Llc | Pneumococcal dosing regimen |
JP5260531B2 (ja) | 2006-10-10 | 2013-08-14 | ワイス・エルエルシー | 肺炎連鎖球菌3型多糖体の精製 |
EP2436700B8 (en) | 2007-03-23 | 2018-08-01 | Wyeth LLC | Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides |
US8540955B2 (en) | 2007-07-10 | 2013-09-24 | Wyeth Llc | Process for producing aluminum phosphate |
MX2011006432A (es) | 2008-12-18 | 2011-09-29 | Wyeth Llc | Metodo para controlar el peso molecular del polisacarido streptococcus pneumoniae serotipo 19a. |
EP2385981B1 (en) | 2008-12-18 | 2019-09-04 | Wyeth LLC | Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon |
NZ597191A (en) | 2009-06-22 | 2013-11-29 | Wyeth Llc | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
TW201136603A (en) | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
EP2575870B1 (en) | 2010-06-04 | 2016-12-07 | Wyeth LLC | Vaccine formulations |
KR20140005892A (ko) | 2010-12-10 | 2014-01-15 | 머크 샤프 앤드 돔 코포레이션 | 면역원성 조성물의 진탕-유도된 응집을 완화시키는 신규한 제제 |
KR102057217B1 (ko) * | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
KR20140075201A (ko) * | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
EP4169929A1 (en) | 2012-12-20 | 2023-04-26 | Pfizer Inc. | Immunogenic compositions comprising pn-serotype 12f |
IL296681B2 (en) * | 2014-01-21 | 2024-09-01 | Pfizer | Immunogenic preparations including conjugated capsular saccharide antigens and their uses |
HUE055553T2 (hu) * | 2014-01-21 | 2021-12-28 | Pfizer | Streptococcus pneumoniae kapszulás poliszacharidok és azok konjugátumai |
EP3957321A3 (en) * | 2014-01-21 | 2022-07-13 | Pfizer Inc. | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
CN106795545A (zh) * | 2014-08-08 | 2017-05-31 | 格林考瓦因有限公司 | 用于生物缀合物产生的修饰宿主细胞和杂合寡糖 |
CN107427568B (zh) | 2015-01-15 | 2021-12-14 | 辉瑞公司 | 用于肺炎球菌疫苗中的免疫原性组合物 |
PE20180172A1 (es) | 2015-05-04 | 2018-01-22 | Pfizer | Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos |
PE20240927A1 (es) | 2015-07-21 | 2024-04-30 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos |
WO2017085602A1 (en) | 2015-11-17 | 2017-05-26 | Pfizer Inc. | Media and fermentation methods for producing polysaccharides in bacterial cell culture |
WO2017085586A1 (en) | 2015-11-20 | 2017-05-26 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
JP7001687B2 (ja) * | 2016-08-05 | 2022-02-04 | サノフィ パスツール インコーポレイティッド | 多価肺炎球菌多糖体-タンパク質コンジュゲート組成物 |
KR20190103256A (ko) * | 2016-12-30 | 2019-09-04 | 수트로박스, 인코포레이티드 | 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체 |
PL3570879T3 (pl) | 2017-01-20 | 2022-06-20 | Pfizer Inc. | Kompozycje immunogenne do zastosowania w szczepionkach przeciw pneumokokom |
US11197921B2 (en) | 2017-01-31 | 2021-12-14 | Merck Sharp & Dohme Corp. | Methods for making polysaccharide-protein conjugates |
KR102650073B1 (ko) | 2017-01-31 | 2024-03-20 | 머크 샤프 앤드 돔 엘엘씨 | 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법 |
WO2018156468A1 (en) | 2017-02-24 | 2018-08-30 | Merck Sharp & Dohme Corp. | Pneumococcal conjugate vaccine formulations |
EP3585427A4 (en) | 2017-02-24 | 2020-12-30 | Merck Sharp & Dohme Corp. | METHODS FOR IMPROVING THE FILTRABILITY OF POLYSACCHARIDE CONJUGATE WITH PROTEIN REACTIONS |
US11219680B2 (en) | 2017-02-24 | 2022-01-11 | Merck Sharp & Dohme Corp. | Polysaccharide-protein conjugates utilizing diphtheria toxin fragment B as a carrier |
KR20200040812A (ko) | 2017-08-16 | 2020-04-20 | 머크 샤프 앤드 돔 코포레이션 | 폐렴구균 접합체 백신 제제 |
AU2018328036B2 (en) * | 2017-09-07 | 2024-03-07 | Merck Sharp & Dohme Llc | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
AU2018328040A1 (en) | 2017-09-07 | 2020-03-19 | Merck Sharp & Dohme Llc | Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein |
CA3074703A1 (en) | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
WO2019050816A1 (en) | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER |
FI3678654T3 (fi) * | 2017-09-07 | 2024-09-02 | Merck Sharp & Dohme Llc | Pneumokokkipolysakkaridit ja niiden käyttö immunogeenisissä polysakkaridi-kantajaproteiini-konjugaateissa |
US20200325020A1 (en) | 2017-10-25 | 2020-10-15 | Merck Sharp & Dohme Corp. | Adjuvanted vaccines |
CN117982633A (zh) * | 2017-12-06 | 2024-05-07 | 默沙东有限责任公司 | 包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法 |
WO2019212844A1 (en) | 2018-04-30 | 2019-11-07 | Merck Sharp & Dohme Corp. | Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide |
EP3787673A4 (en) | 2018-04-30 | 2022-04-27 | Merck Sharp & Dohme Corp. | METHODS FOR PRODUCING CAPSULAR CARRIER PROTEIN-POLYSACCHARIDE CONJUGATES OF STREPTOCOCCUS PNEUMONIAE |
CN112074294A (zh) | 2018-04-30 | 2020-12-11 | 默沙东公司 | 从冻干球生产肺炎链球菌荚膜多糖载体蛋白缀合物的方法 |
US20210223262A1 (en) | 2018-06-07 | 2021-07-22 | Merck Sharp & Dohme Corp. | Lyosphere critical reagent kit |
CA3120922A1 (en) | 2018-12-12 | 2020-06-18 | Pfizer Inc. | Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof |
SG11202106541WA (en) | 2018-12-19 | 2021-07-29 | Merck Sharp & Dohme | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
CA3136278A1 (en) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
BR112021024491A8 (pt) | 2019-06-05 | 2023-04-11 | Merck Sharp & Dohme | Composição imunogênica, e, método para prevenir, tratar ou melhorar uma infecção, doença ou condição |
BR112021024393A8 (pt) | 2019-06-05 | 2023-01-31 | Merck Sharp & Dohme | Um conjugado de polissacarídeo-proteína pneumocócico de sorotipo 35b imunogênico e processo de conjugação para fabricar o mesmo |
-
2018
- 2018-02-20 EP EP18757315.9A patent/EP3589314A4/en active Pending
- 2018-02-20 MX MX2019009867A patent/MX2019009867A/es unknown
- 2018-02-20 KR KR1020197027396A patent/KR20190121330A/ko not_active Application Discontinuation
- 2018-02-20 AU AU2018225099A patent/AU2018225099B2/en active Active
- 2018-02-20 JP JP2019546002A patent/JP2020514326A/ja active Pending
- 2018-02-20 BR BR112019017560A patent/BR112019017560A2/pt unknown
- 2018-02-20 KR KR1020247001331A patent/KR20240011879A/ko active Search and Examination
- 2018-02-20 CN CN201880013793.7A patent/CN110337307A/zh active Pending
- 2018-02-20 US US16/487,550 patent/US11090374B2/en active Active
- 2018-02-20 WO PCT/US2018/018729 patent/WO2018156491A1/en unknown
- 2018-02-20 CA CA3050120A patent/CA3050120A1/en active Pending
-
2019
- 2019-08-19 MX MX2023001947A patent/MX2023001947A/es unknown
- 2019-08-19 MX MX2023001948A patent/MX2023001948A/es unknown
-
2021
- 2021-07-07 US US17/369,230 patent/US20210330778A1/en not_active Abandoned
- 2021-07-07 US US17/369,177 patent/US20210330777A1/en not_active Abandoned
-
2023
- 2023-01-05 JP JP2023000606A patent/JP2023036953A/ja active Pending
- 2023-06-22 US US18/339,723 patent/US20240139303A1/en active Pending
-
2024
- 2024-05-24 JP JP2024084665A patent/JP2024112952A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210330778A1 (en) | 2021-10-28 |
RU2019129503A3 (es) | 2021-06-25 |
US11090374B2 (en) | 2021-08-17 |
JP2024112952A (ja) | 2024-08-21 |
JP2020514326A (ja) | 2020-05-21 |
US20240139303A1 (en) | 2024-05-02 |
EP3589314A4 (en) | 2021-04-21 |
AU2018225099A1 (en) | 2019-07-25 |
US20210330777A1 (en) | 2021-10-28 |
CA3050120A1 (en) | 2018-08-30 |
AU2018225099B2 (en) | 2024-08-22 |
CN110337307A (zh) | 2019-10-15 |
MX2023001947A (es) | 2023-03-14 |
JP2023036953A (ja) | 2023-03-14 |
US20200054733A1 (en) | 2020-02-20 |
EP3589314A1 (en) | 2020-01-08 |
WO2018156491A1 (en) | 2018-08-30 |
KR20240011879A (ko) | 2024-01-26 |
MX2019009867A (es) | 2019-10-02 |
BR112019017560A2 (pt) | 2020-04-07 |
RU2019129503A (ru) | 2021-03-24 |
KR20190121330A (ko) | 2019-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023001948A (es) | Inmunogenicidad mejorada de conjugados de polisacarido-proteina de streptococcus pneumoniae. | |
MX2022014850A (es) | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. | |
MX2022009927A (es) | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. | |
MX2022009928A (es) | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. | |
JOP20200141A1 (ar) | تركيبات مشتملة على متقارنات بروتين عديد سكاريد المكورات العقدية الرئوية وطرق استخدامها | |
MX2020002555A (es) | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. | |
NZ755769A (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
MX371453B (es) | Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos. | |
PH12017501898A1 (en) | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof | |
NZ752348A (en) | Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates | |
WO2020131763A3 (en) | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof | |
IN2014DN09791A (es) | ||
EA201990451A1 (ru) | Композиция многовалентных пневмококковых конъюгатов капсульного полисахарида с белком-носителем и ее применение | |
MX2020002084A (es) | Conjugados de peptido, proceso de conjugacion y usos de los mismos. | |
BR112017028395A2 (pt) | ?polissacarídeo capsular bacteriano, conjugado, e, composição farmacêutica? |